America Is About to Go Over a Peptide Cliff

An FDA advisory committee voted to allow compounding pharmacies to produce BPC-157, a peptide with minimal human safety data and no standard approval process, despite FDA researchers citing weak evidence and unknown safety profiles. The decision opens a path for telehealth and wellness companies to sell peptides legally that have previously been sourced from unregulated grey-market vendors.

This Wire brief tracks EternaFusion, and It sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.